Literature DB >> 12492570

Tumour-associated antigens in multiple myeloma.

Catherine Pellat-Deceunynck1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12492570     DOI： 10.1046/j.1365-2141.2003.03760.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

Authors:  Frits van Rhee; Susann M Szmania; Fenghuang Zhan; Sushil K Gupta; Mindy Pomtree; Pei Lin; Ramesh B Batchu; Amberly Moreno; Guilio Spagnoli; John Shaughnessy; Guido Tricot
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

2.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

3.  B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Authors:  Zhao-Yang Lu; Maud Condomines; Karin Tarte; Laure Nadal; Marie Claude Delteil; Jean François Rossi; Christophe Ferrand; Bernard Klein
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

4.  Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

Authors:  Simona Blotta; Pierfrancesco Tassone; Rao H Prabhala; Piersandro Tagliaferri; David Cervi; Samir Amin; Jana Jakubikova; Yu-Tzu Tai; Klaus Podar; Constantine S Mitsiades; Alessandro Zullo; Brunella Franco; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

5.  Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Authors:  Louise M E Müller; Matthew Holmes; Joanne L Michael; Gina B Scott; Emma J West; Karen J Scott; Christopher Parrish; Kathryn Hall; Sina Stäble; Victoria A Jennings; Matthew Cullen; Stewart McConnell; Catherine Langton; Emma L Tidswell; Darren Shafren; Adel Samson; Kevin J Harrington; Hardev Pandha; Christy Ralph; Richard J Kelly; Gordon Cook; Alan A Melcher; Fiona Errington-Mais
Journal:  J Immunother Cancer       Date:  2019-07-01       Impact factor: 13.751

6.  Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.

Authors:  Nandakumar Packiriswamy; Deepak Upreti; Yumei Zhou; Rehan Khan; Amber Miller; Rosa M Diaz; Cliona M Rooney; Angela Dispenzieri; Kah-Whye Peng; Stephen J Russell
Journal:  Leukemia       Date:  2020-04-23       Impact factor: 11.528

7.  Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.

Authors:  Louise M E Müller; Gemma Migneco; Gina B Scott; Jenny Down; Sancha King; Basem Askar; Victoria Jennings; Babatunde Oyajobi; Karen Scott; Emma West; Christy Ralph; Adel Samson; Elizabeth J Ilett; Munitta Muthana; Matt Coffey; Alan Melcher; Christopher Parrish; Gordon Cook; Michelle Lawson; Fiona Errington-Mais
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.